Ophthalmology. Retina · 2019
Stereopsis after Intravitreal Ranibizumab Injections for Branch Retinal Vein Occlusion.
Контролируемое клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Morikawa Shohei, Okamoto Fumiki, Sugiura Yoshimi, Murakami Tomoya, Hiraoka Takahiro, Oshika Tetsuro
Аннотация
PURPOSE: To evaluate stereopsis before and after intravitreal ranibizumab (IVR) injections in patients with branch retinal vein occlusion (BRVO) and investigate the relationship between stereopsis and retinal microstructure.
DESIGN: Prospective, observational, controlled study.
PARTICIPANTS: Thirty-two eyes of 32 patients undergoing IVR treatment for BRVO and 28 eyes of age-matched healthy control participants.
METHODS: Stereopsis was measured using the Titmus stereo test (TST) and TNO stereo test before and 1, 2, 3, 4, 5, and 6 months after treatment.
MAIN OUTCOME MEASURES: Stereopsis, best-corrected visual acuity (BCVA), duration of disease, central retinal thickness, status of the external limiting membrane, ellipsoid zone, and external limiting membrane, and serous retinal detachment (SRD) after treatment.
RESULTS: Treatment with IVR significantly improved the TST (P < 0.001) and TNO stereo test (P < 0.05) scores as well as BCVA (P < 0.001) and central retinal thickness (P < 0.005). Stereopsis after IVR injection in eyes with BRVO was significantly worse than that in healthy control participants (TST, P < 0.001; TNO stereo test, P < 0.001). The TST and TNO stereo test scores were correlated significantly with BCVA and the presence of SRD at baseline. After 6 months of treatment, an association of TST and TNO stereo test scores with BCVA and status of the external limiting membrane and ellipsoid zone was observed. Stereopsis after treatment showed a significant relationship with BCVA and presence of SRD at baseline.
CONCLUSIONS: Administration of IVR for BRVO improved early stereopsis, albeit not to a normal level. Presence of SRD and visual acuity were predictors of stereopsis after treatment in patients with BRVO.
DESIGN: Prospective, observational, controlled study.
PARTICIPANTS: Thirty-two eyes of 32 patients undergoing IVR treatment for BRVO and 28 eyes of age-matched healthy control participants.
METHODS: Stereopsis was measured using the Titmus stereo test (TST) and TNO stereo test before and 1, 2, 3, 4, 5, and 6 months after treatment.
MAIN OUTCOME MEASURES: Stereopsis, best-corrected visual acuity (BCVA), duration of disease, central retinal thickness, status of the external limiting membrane, ellipsoid zone, and external limiting membrane, and serous retinal detachment (SRD) after treatment.
RESULTS: Treatment with IVR significantly improved the TST (P < 0.001) and TNO stereo test (P < 0.05) scores as well as BCVA (P < 0.001) and central retinal thickness (P < 0.005). Stereopsis after IVR injection in eyes with BRVO was significantly worse than that in healthy control participants (TST, P < 0.001; TNO stereo test, P < 0.001). The TST and TNO stereo test scores were correlated significantly with BCVA and the presence of SRD at baseline. After 6 months of treatment, an association of TST and TNO stereo test scores with BCVA and status of the external limiting membrane and ellipsoid zone was observed. Stereopsis after treatment showed a significant relationship with BCVA and presence of SRD at baseline.
CONCLUSIONS: Administration of IVR for BRVO improved early stereopsis, albeit not to a normal level. Presence of SRD and visual acuity were predictors of stereopsis after treatment in patients with BRVO.